Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 3, 2005, Pages 445-451

  Lesho, Emil ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Aerosolized; Delivery of antibiotics; Healthcare associated; Inhaled; Nebulized; Nosocomial pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; COLISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; PLACEBO; POLYMYXIN; POLYMYXIN B; SODIUM CHLORIDE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; HIGH RISK PATIENT; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; NEBULIZER; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMONIA; REVIEW; SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; PNEUMONIA, BACTERIAL; RESPIRATORY THERAPY; VENTILATORS, MECHANICAL;

EID: 21044454474     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.3.445     Document Type: Review

References (50)

1. Spellburg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38, 1279-1286 (2004).
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 23,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
3. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance System Report, data summary from January 1992 through to June 2003, issued August 2003. Am. J. Infect. Control 31, 481-498 (2003).
4. Ramsey BW, Dorkin HL, Eisenberg JD et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 45, 2502-2509 (1993).
5. Tobramycin Solution for Inhalation (TOBI®). PathoGenesis Corporation, Seattle, WA, USA (1998).
6. Ryan G, Mukhopadhyay S, Singh M. Nebulized antipseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst. Rev. 3, CD001021 (2003).
7. Touw DJ, Jacobs FAH, Brimicombe RE et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 41, 184-187 (1997).
8. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis. 132, 761-765 (1985).
9. Smaldone GC. Aerosolized antibiotics in mechanically ventilated patients. Respir. Care. 49, 635-639 (2004).
10. Goldstein I, Wallet F, Nicolas-Robin A et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 166, 1375-1381 (2002).
11. Elman M, Goldstein I, Charles-Hugo MD et al. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 97, 199-206 (2002).
12. Gilbert DN. Aminoglycosides. In: Principles and Practice of Infectious Diseases. Sixth Edition. Mandell DL, Bennett JC, Dolin R (Eds), Elsivier Inc., PA, USA, 328-356 (2005).
13. Smaldone GC, Palmer LB. Aerosolized antibiotics: current and future. Respir. Care 45, 667-675 (2000).
14. Hamill RJ, Houston ED, Georghiu PR et al. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann. Intern. Med. 122, 762-766 (1995).
15. Craven DE, Lichtenberg DA, Goularte TA, Make BJ, McCabe WR. Contaminated medication nebulizers in mechanical ventilator circuits: source of bacterial aerosols. Am. J. Med. 77, 834-838 (1984).
16. Beaty CD, Ritz RH, Benson MS. Continuous in-line nebulizers complicate pressure support ventilation. Chest 96, 1360-1363 (1989).
17. Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers: how reliable are they? Chest 101, 16-19 (1992).
18. Summer W, Elston R, Tharpe S, Nelson S, Haponik EF. Aerosol bronchodilator delivery methods: relative impact on pulmonary function and cost of respiratory care. Arch. Intern. Med. 149, 618-623 (1989).
19. Bowton DL, Goldsmith WM, Haponik EF. Substitution of metered-dose inhalers for hand-held nebulizers: success and cost savings in a large, acute-care hospital. Chest 101, 305-308 (1992).
20. Klesper ME. Role of nebulized antibiotics for the treatment of respiratory infections. Curr. Opin. Infect. Dis. 17, 109-112 (2004).
21. O'Riordan TG. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir. Care 45, 836-845 (2000).
22. Dhand R, Tobin MJ. Inhaled bronchodilator therapy in mechanically ventilated patients. Am. J. Respir. Crit. Care Med. 156, 3-10 (1997).
23. Svartengren M, Anderson M, Philipson K, Camner P. Human lung deposition of particles suspended in air or in helium/oxygen mixture. Exp. Lung Res. 15, 575-585 (1989).
24. Goode ML, Fink JB, Dhand R, Tobin MJ. Improvements in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am. J. Respir. Crit. Care Med. 163, 109-114 (2001).
25. O'Riordan TG, Greco MJ, Perry RJ, Smaldone GC. Nebulizer function during mechanical ventilation. Am. Rev. Pespir. Dis. 145, 1117-1122 (1992).
26. O'Doherty MJ, Thomas SHL, Page CJ, Treacher DF, Nunan TO. Delivery of a nebulized aerosol to a lung model during mechanical ventilation: effect of ventilator settings and nebulizer type, position, and volume of fill. Am. Rev. Respir. Dis. 146, 383-388 (1992).
27. Diot P, Morra L, Smaldone GC. Albuterol delivery in a model of mechanical ventilation: comparison of metered-dose inhaler and nebulizer efficiency. Am. J. Respir. Crit. Care Med. 152, 1391-1394 (1995).
28. Fink JB, Dhand R, Duarte AG, Jenne JW, Tobin MJ. Deposition of aerosol from metered-dose inhaler during mechanical ventilation: an in vitro model. Am. J. Respir. Crit. Care Med. 154, 382-387 (1996).
29. Feeley TW, Du Moulin GC, Hedey-Whyte J, Bushnell LS, Gilbert JP, Feingold DS. Aerosol polymyxin and pneumonia in seriously ill patients. N. Engl. J. Med. 293, 471-475 (1975).
30. Klick JM, Du Moulin GC, Hedley-Whyte J, Teres D, Bushnell LS, Feingold DS. Prevention of Gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis. J. Clin. Invest. 555, 514-519 (1975).
31. Klastersky J, Hensgens C, Noterman J, Mouawad E, Meunier-Carpentier F. Endotracheal antibiotics for the prevention of tracheobronchial infections in tracheotomized unconscious patients. A comparative study of gentamicin and aminosidin-polymyxin B combination. Chest 68, 302-306 (1975).
32. Klastersky J, Huysmans E, Weerts D, Hensgens C, Daneau D. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study. Chest 65, 650-654 (1974).
33. Klastersky J, Cappel R, Noterman J, Snoeck J, Geuning C, Mouawad E. Endotracheal gentamicin for the prevention of bronchial infections in patients with tracheotomy. Int. J. Clin. Pharmacol. 7, 279-286 (1973).
34. Klastersky J, Carpentier-Meunier F, Kahan-Coppens L et al. Endotracheally administered antibiotics for Gram-negative bronchopneumonia. Chest 75, 586-591 (1979).
35. Rathgeber J, Zielmann S, Panzer C et al. Prevention of pneumonia by endotracheal micronbulization of tobramycin. Anaesthesiol. Intensivemed. Notfallmed. Schmerzther. 28, 23-29 (1993).
36. Rouby JJ, Poete P. de Lassale ME et al. Prevention of Gram-negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Intensive Care Med. 20, 187-192 (1994).
37. Wood C, Boucher BA, Croce MA, Hanes SD, Herring VL, Fabian TC. Acrosolized ceftazidime for prevention on ventilator-associated pneumonia and drug effects on the pro-inflammatory response in critically ill trauma patients. Pharmacotherapy 22, 972-982 (2002).
38. Wood CG, Boucher BA. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 20, 166-181 (2000).
39. Dodek P, Keenan S, Cook D. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann. Intern. Med. 141, 305-313 (2004).
40. Stoutenbeek CP, van Saene HKF, Miranda DR, Zandsra DF, Langrehr D. Nonsocomial Gram-negative pneumonia in critically ill patients. Intensive Care Med. 12, 419-423 (1986).
41. LeConte P, Potel G, Clementi E et al. Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study. Presse Med. 29, 76-78 (2000).
42. Orriols R, Roig J, Ferrer J et al. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir. Med. 93, 476-480 (1999).
43. Ruijgrok EJ, Vulto AG, Van Etten EWM. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J. Antimicrob. Chemother. 48, 89-95 (2001).
44. Sobieszczyk ME, Furuya EY, Hay CM et al. Combination therapy with polymyxin B for the treatment of multi-drug resistant Gram-negative respiratory tract infections. J. Antimicrob. Chemother. 54, 566-569 (2004).
45. Michalopoulos A, Kasiakou SK, Mastora Z, Rellow K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multi-drug resistant Gram-negative bacteria in patients without cystic fibrosis. Crit. Care. 9, R53-R59 (2005).
46. Brown RB, Kruse JA, Counts GW et al. Double-blind study of endotracheal tobramycin in the treatment of Gram-negative bacterial pneumonia. Antimicrob. Agents Chemother. 34, 269-272 (1990).
47. Sherry E, Warnke PH. Successful use of an inhalational phytochemical to treat pulmonary tuberculosis: a case report. Phytomedicine 11, 95-97 (2004).
48. Erjavec Z, Woolthuis GM, de Vries-Hospers HG et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur. J. Clin. Microbiol. Infect. Dis. 16, 364-368 (1997).
49. Herrenstein B, Kern WV, Schmeiser T et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann. Hematol. 58, 21-26 (1994).
50. Schwartz S, Behre G, Heinemann V et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 93, 3654-3661 (1999).